NONMEM Users Network Archive

Hosted by Cognigen

Post-doctoral fellow/PhD position in Translational Pharmacology

From: D'Agate, Salvatore <s.d'agate>
Date: Thu, 24 Sep 2020 15:32:11 +0000

Drug-disease-immune system interactions and dose rationale for drug combina=
tions in tuberculosis.

Background: Tuberculosis is the leading cause of death by an infectious dis=
ease worldwide. Standard tuberculosis treatment is based on a combination r=
egimen of four drugs that were all developed more than 60 years ago. Treatm=
ent lasts for at least six months and, in the case of resistance to the sta=
ndard drugs, can be as long as two years. The current drugs are inefficient=
 by today's standards and a new, faster-acting and safer treatment is requi=
red to reduce the length of therapy and to overcome the threat of drug-resi=
stant strains. Until now, the development of new drugs has been slow and th=
eir incorporation into tuberculosis treatment regimens conducted in a seque=
ntial manner.

While pharmacokinetic-pharmacodynamic concepts and advanced quantitative cl=
inical pharmacology principles have been integrated into the clinical devel=
opment of compounds across many therapeutic areas, human dose prediction an=
d early clinical evaluation of the efficacy and safety of candidate molecul=
es for tuberculosis remains empirical. Innovative approaches are required t=
o enable effective translation of nonclinical data, providing insight into =
the selection of rational combinations and optimised clinical trial designs=
. Of interest is the interplay between the immune system and drug-induced a=
ntibacterial activity.

A PhD fellowship and a post-doctoral research fellow position in translatio=
nal clinical pharmacology have been created to support the activities of an=
 ambitious consortium including European and global organisations responsib=
le for the development and evaluation of novel candidate molecules for the =
treatment of tuberculosis. The primary objective of the research programme=
 will be to establish the pharmacokinetic-pharmacodynamic (PKPD) properties=
 of drug candidates progressing into clinical development. Different approa=
ches will be applied to ensure

1) systematic translation of pharmacokinetic and PKPD concepts from in vitr=
o and in vivo systems to humans and
2) optimisation of clinical study protocols (e.g. first-time-in-humans, ear=
ly bactericidal activity).

Required skills: In addition to enthusiasm, motivation and independent thin=
king, candidates must have working knowledge of pharmacokinetic-pharmacodyn=
amic modelling and simulation, including prior experience with advanced sta=
tistical principles (nonlinear mixed effects modelling, Bayesian statistics=
, clinical trial simulations). Strong programming skills in R language, RSt=
udio and NONMEM are essential.

Willingness to learn and integrate knowledge from across different therapeu=
tic areas. Behavioural attributes such as teamwork, accurate listening, str=
ategic thinking, along with very good oral and written English language ski=
lls will be critical for the successful implementation of the project.

PhD fellowship: Candidates with a degree in Medicine, Pharmaceutical Scienc=
es, Biomedical Sciences or Bioengineering are encouraged to apply, especial=
ly those with a MSc/MRes thesis or equivalent research experience in PKPD m=
odelling and simulation.

Post-doctoral research fellow: Candidates should have completed a PhD in a =
relevant discipline (quantitative clinical pharmacology, pharmacometrics, p=
opulation pharmacokinetics, PKPD modelling, PBPK modelling), and have publi=
shed their research in a peer reviewed journal.

The successful candidates will be co-located with the modelling team at the=
 CNR (Consiglio Nazionale delle Ricerche) in Rome, Italy. Applicants for th=
e PhD fellowship should be nationals of a EU member state.

Further details on the application procedures can be obtained by email. Ple=
ase contact Prof O. Della Pasqua (o.dellapasqua
), including a short CV.

Deadline for applications: 30th September 2020.

Kind regards,

Salvatore D'Agate
Clinical Pharmacology & Therapeutics
School of Life and Medical Sciences
University College London
E-mail: s.d'agate

Received on Thu Sep 24 2020 - 11:32:11 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: